Clinical trials: RANDOMIZED
Healthy
A Study To Evaluate Whether Food Affects The Plasma Drug Levels Of A 35 mg Single Dose Of PF-04447943 Taken Orally In Healthy Adult Participants
The purpose of the study is to compare the plasma drug levels of PF-04447943 when taken as a 35 mg tablet after a high fat meal compared to when taken after fasting.
- Trial name
- NCT00886093
- Testing
- PF-04447943
- Where
- United States
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Pfizer
Aortic Stenosis
PERIGON Japan Trial
The purpose of this study is to evaluate the safety and effectiveness of the 17mm MDT-2215 aortic valve bioprosthesis.
- Trial name
- NCT02686814
- Testing
- 17mm MDT-2215 aortic valve bioprosthesis
- Where
- 10 sites in Japan
- Volunteers
- 25 people
- Sponsor
- Medtronic Cardiac Surgery
Obesity
Safety and Efficacy of Different Combinations of Zonisamide-CR Plus Bupropion-SR to Treat Uncomplicated Obesity
The purpose of this study is to determine which of seven combinations of Zonisamide CR and Bupropion SR gives the best weight loss and is safe and well tolerated for the treatment of obesity not associated with the complications…
- Trial name
- NCT00339014
- Testing
- Zonisamide CR and Bupropion SR
- Where
- 15 sites in United States
- Volunteers
- 611 people
- Sponsor
- Orexigen Therapeutics, Inc
Healthy
Safety, Tolerability, and Pharmacokinetic Evaluations of CKR-051 After Transdermal Administration in Healthy Male Subjects
This study will evaluate the safety, tolerability, and pharmacokinetics (PK) of CKR-051 in healthy participants. This study aiming to develop an agent for skin regeneration; potential treatments include acute and chronic wounds…
- Trial name
- NCT05833906
- Testing
- CKR-051 Dose 1, CKR-051 Dose 2, CKR-051 Dose 3
- Where
- South Korea
- Volunteers
- 52 people, healthy volunteers welcome
- Sponsor
- CK Regeon Inc.
Influenza, Human, Pneumonia, Pneumococcal
Evaluation of Immunogenicity and Safety of Combined Immunization of COVAX (Produced in Wuhan) and PPV23 / IIV4
Subjects will be recruited and divided into 3 groups: Experimental Group (468 subjects): 1st dose : combined vaccination of COVAX+PPV23, 2nd dose: combined vaccination of COVAX+IIV4; Control Group A (468 subjects): 1st dose…
- Conditions
- Influenza, Human, Pneumonia, Pneumococcal, COVID-19 Pneumonia
- Trial name
- NCT05079152
- Testing
- COVAX+PPV23;COVAX+IIV4, COVAX only (1st and 2nd dose), PPV23 for the 1st dose and IIV4 for the 2nd dose
- Where
- 3 sites in China
- Volunteers
- 1,404 people, healthy volunteers welcome
- Sponsor
- China National Biotec Group Company Limited
Leukemia
Quizartinib or Placebo Plus Chemotherapy in Newly Diagnosed Patients With FLT3-ITD Negative AML
This study will compare the effects of Quizartinib versus placebo in combination with chemotherapy in participants with newly diagnosed FMS-like tyrosine kinase 3 (FLT3)-internal tandem duplication (ITD) negative acute myeloid…
- Trial name
- QuANTUM-WILD (NCT06578247)
- Testing
- Quizartinib, Chemotherapy
- Where
- 284 sites in United States, Australia and 26 more
- Volunteers
- 700 people
- Sponsor
- Daiichi Sankyo
Influenza
Clinical Study for Safety and Immunogenicity Study of Influenza Vaccine
The goal of the study is to assess the safety and immune response after vaccination with different doses and vaccination schedules of virosomal influenza vaccine.
- Trial name
- NCT01617239
- Testing
- Virosomal influenza vaccine
- Where
- Belgium
- Volunteers
- 84 people, healthy volunteers welcome
- Sponsor
- Crucell Holland BV
Mild Cognitive Impairment (MCI), Parkinson Disease (PD)
A Study of CST-2032 in Subjects With Cognitive Impairment
This study will evaluate the effects of CST-2032 when administered with pre-administered CST-107 on safety, tolerability, cognition, cerebral perfusion, and cerebral metabolism in patients with cognitive impairment.
- Trial name
- NCT05033912
- Sponsor
- CuraSen Therapeutics, Inc.
Neoplasms
Phase I Study of BAY73-4506 in Chinese Patients With Advanced, Refractory Solid Tumors
This will be an uncontrolled, open-label, non-randomized, phase I study. The primary objectives of this study are to define the pharmacokinetics (PK) and to evaluate the safety and tolerability of Regorafenib administered orally…
- Trial name
- NCT01096030
- Testing
- Regorafenib (Stivarga, BAY73-4506)
- Where
- 4 sites in Hong Kong, Singapore
- Volunteers
- 33 people
- Sponsor
- Bayer
Healthy Volunteers
Skin Safety Study to Evaluate the Sensitizing Potential in Healthy Volunteers
This is a single center, randomized, controlled, within subject comparison, multiple dose study to determine the sensitization potential of M518101 on normal skin under occlusive patch condition.
- Trial name
- NCT02256930
- Testing
- M518101, M518101 Vehicle, Sodium lauryl sulfate
- Where
- United States
- Volunteers
- 240 people, healthy volunteers welcome
- Sponsor
- Maruho North America Inc.
Asthma
A Study To Assess The Duration Of Action Of PF-03526299 In Asthmatic Subjects Following Allergen Challenge
The purpose of this study is to find out how long the effect of PF-03526299 last after it is inhaled by assessing the lung function of mild asthma patients after they have been exposed to allergen
- Trial name
- NCT01299467
- Testing
- Active (PF-03526299)
- Sponsor
- Pfizer
Blepharospasm
IncobotulinumtoxinA (Xeomin) Versus Placebo in the Treatment of Blepharospasm
Patients received one injection with incobotulinumtoxinA (Xeomin) or placebo at baseline. Thereafter, all patients who entered the Open-Label Extension Period (OLEX) received up to five injection sessions of incobotulinumtoxinA…
- Trial name
- NCT00406367
- Testing
- incobotulinumtoxinA (Xeomin)
- Where
- 2 sites in United States, Canada
- Volunteers
- 109 people
- Sponsor
- Merz Pharmaceuticals GmbH
Healthy
A Study to Evaluate How Well Single and Multiple Doses of GLPG4399 Are Tolerated in Healthy, Adult Subjects
The main purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of single (part 1) and multiple ascending (part 2) oral doses of GLPG4399, in adult, healthy, male subjects.
- Trial name
- NCT04653467
- Testing
- GLPG4399 oral suspension, GLPG4399 capsules
- Where
- Canada
- Volunteers
- 88 people, healthy volunteers welcome
- Sponsor
- Lakefront Biotherapeutics NV
Postmenopausal Women With Osteoporosis
Study Investigating PK, PD, Efficacy, Safety, and Immunogenicity of Biosimilar Denosumab (GP2411) in Patients With Postmenopausal Osteoporosis
This study was conducted to assess if there were any clinically meaningful differences in pharmacokinetics (PK), pharmacodynamics (PD), efficacy, safety, or immunogenicity between GP2411 (proposed biosimilar denosumab) and…
- Trial name
- NCT03974100
- Testing
- GP2411, EU-Prolia (EU-authorized Prolia®)
- Where
- 42 sites in United States, Bulgaria and 4 more
- Volunteers
- 527 people
- Sponsor
- Sandoz
Multiple Sclerosis
Effect of MD1003 in Chronic Visual Loss Related to Optic Neuritis in Multiple Sclerosis
The purpose of this study is to demonstrate the superiority of MD1003 over placebo in the visual improvement of patients suffering from chronic visual loss resulting from multiple sclerosis related optic neuritis.
- Trial name
- MS-ON (NCT02220244)
- Testing
- MD1003 100mg capsule
- Where
- 20 sites in France, United Kingdom
- Volunteers
- 105 people
- Sponsor
- MedDay Pharmaceuticals SA
Skin Graft
Compare of Petrolatum Gauze, Allevyn, and New Dressing, Betafoam® in the Management of Split-Thickness Skin Graft Donor Site
This study is a randomized, controlled, multi-centre, open-label, phase IV study. Total 81 patients will be enrolled in this study.
- Trial name
- NCT02543034
- Testing
- Betafoam Wound Dressing, Petrolatum Gauze, Allevyn Wound Dressing
- Where
- South Korea
- Volunteers
- 105 people
- Sponsor
- Mundipharma Korea Ltd
Idiopathic Parkinson's Disease
Double-Blind, Multicenter, Sham Surgery Controlled Study of CERE-120 in Subjects With Idiopathic Parkinson's Disease
The purpose of this double blind study is to determine whether CERE-120 (adeno-associated virus serotype 2 [AAV2]-neurturin [NTN]) is effective and safe in the treatment of patients with idiopathic Parkinson's Disease.
- Trial name
- NCT00400634
- Testing
- CERE-120 (Adeno-Associated Virus Serotype 2 [AAV2]-Neurturin [NTN])
- Where
- 9 sites in United States
- Volunteers
- 58 people
- Sponsor
- Sangamo Therapeutics
Alzheimer's Disease
Evaluation of the Efficacy and Safety of Azeliragon (TTP488) in Patients With Mild Alzheimer's Disease
This is a study to evaluate the efficacy and safety of azeliragon in patients with mild Alzheimer's disease. Patients will receive either azeliragon or placebo with a patient's participation lasting approximately 18 months.
- Trial name
- STEADFAST (NCT02080364)
- Testing
- Azeliragon
- Where
- 115 sites in United States, Australia and 5 more
- Volunteers
- 880 people
- Sponsor
- vTv Therapeutics
Healthy
A Phase 1 Study of PROT-001.
A Phase 1, First-In-Human, Randomized, Double-Blind, Placebo-Controlled Multi-Part Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Ascending Doses of PROT-001, the Effect of…
- Trial name
- NCT06981299
- Testing
- PROT-001, Rosuvastatin 10mg, Digoxin 0.25 mg
- Where
- Australia
- Volunteers
- 102 people, healthy volunteers welcome
- Sponsor
- Protego Biopharma Pty Ltd
Crohn's Disease
A Study of TRK-170 for the Treatment of Crohn's Disease
In Crohn's Disease Patients To evaluate the efficacy of TRK-170 To evaluate the PK characteristics of TRK-170 To assess the safety of TRK-170
- Trial name
- NCT01345799
- Testing
- TRK-170
- Where
- 13 sites in Belgium, Bulgaria and 11 more
- Volunteers
- 123 people
- Sponsor
- Toray Industries, Inc
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.